HTFL Company Profile and Key Details

HTFL has shown mixed momentum, gaining 7.55% over the past week and 1.24% over the past quarter, though year-to-date performance is up 17.29%. Short-term trend indicators are bullishly aligned (SMA20 -6.17%, SMA50 -17.01%, SMA200 -23.05%). The stock’s 14-day RSI is 42.92 (neutral), while the ATR of 2.14 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -41.56% below its high and over 19.67% above its low. Average 10-day trading volume of 1.06 million shares is below the 3-month average of 1.61 million, indicating normal recent market interest.

Heartflow, Inc. Common Stock has 83.12 million shares outstanding. The public float is 53.73 million shares, elevated short interest at 0.56% of float. This equals 463.10 thousand shares. The short ratio is 0.22 days. Institutional investors hold 52.38% of the float. Insiders own 20.87%. Bain Capital Life Sciences Investors, LLC holds 10.45 million shares, Farquhar John C.M. has 571.72 thousand shares and Rogers Campbell has 81.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.26 million shares across 9 transactions.

Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $43.00 to $35.00. The high target offers 48.02% upside. The low target suggests 20.48% downside. The mean target is $38.00. This offers 30.81% upside. Heartflow, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -0.14%. The prior quarter beat by 630.0%. Over the last six quarters, Apple has recorded several small beats. These include 630.0% in September 19, 2025.

Our AI price prediction model suggests that Heartflow, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.03%, with price expected at $29.64 by April 28, 2026, within a range of $27.66 to $31.76 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by July 13, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected loss of -50.95%, with price at $14.25 by April 14, 2027, within a range of $13.21 to $15.27.

Heartflow, Inc. Common Stock (NASDAQ:HTFL) shares are up 17.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Heartflow, Inc. Common Stock trading at a premium to the broader market with a P/E of -91.35. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.00, suggesting 30.81% upside. Our AI forecast model points to short-term strength (2.03% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-50.95% over one year), with expected trading ranges indicating moderate volatility.

Heartflow, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.14. This means the shares are trading above this model’s fair value.

Heartflow, Inc. Common Stock (NASDAQ:HTFL) closed at $29.89 USD, gaining $0.66 (2.26%) from the previous close of $29.23. The stock is currently mid-range between its 52-week high and low $20.13 and $41.22. With a market capitalization of about $2.56 billion, Heartflow, Inc. Common Stock is classified as a mid-cap and shows market-like volatility (beta ~1.03). Key stats such as the average daily volume over the past year has been around 1.60 million shares, volume is running light vs its 52-week average. Headquartered in Mountain View, CA, Heartflow, Inc. Common Stock operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO John Farquhar, the company employs approximately 626 people and listed since August 07, 2025. HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide.

Heartflow, Inc. Common Stock trades at a P/E ratio of -91.35, slightly below the S&P 500 average, with a price-to-sales ratio of 14.1 and a price-to-book ratio of 35.49 reflecting a rich premium to book value. The P/FCF stands at -42.05, also below market averages. Compared to sector medians, Heartflow, Inc. Common Stock P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.